Dave Ricks
📊 CEO Reputation Score
FY2025 vs FY2024 · Source: SEC EDGAR filings- Profit (net income): $10.6B → $20.6B (+94.9% YoY) — fiscal 2025 vs fiscal 2024
🧭 Personal Philosophy & Quotes
Ricks' philosophy is a social contract he states openly: Lilly's job is to invent medicines that didn't exist, earn a strong but time-limited reward while they're patented, and then let them go cheap as generics — the model he invoked when cutting insulin prices and capping out-of-pocket costs at $35. Against that, he is ruthless about the innovation engine itself: concentrate R&D, build manufacturing ahead of demand (tens of billions in new US plants), and cut out 'rent-taking' middlemen (LillyDirect). For investors, he is the purest R&D-compounder on this list — named Chief Executive magazine's CEO of the Year for 2025 after Lilly became the world's most valuable drugmaker.
Operating principles
- Innovation is the whole business model
- Patent rewards are earned — and temporary
- Build capacity before demand arrives
“I think a bet on Lilly is to bet we can keep on inventing new things, not just sell the ones we've invented.”— Quoted in CEO Today, Top 50 CEOs profile
“No one should have to ration their insulin.”— NPR interview on Lilly's insulin price cuts, Mar 2023
Overview
Born in Bloomington, Indiana — the user's hometown in this project's case, and Lilly's home state — Ricks joined the company straight from his MBA in 1996 and worked business development, marketing, country management (including China) and drug development before becoming CEO on 1 January 2017. He then presided over the GLP-1 era: Mounjaro and Zepbound took Lilly's market value from ~$90bn to over $1.2 trillion.
Education
- B.S. Industrial Management — Purdue University (1990)
- MBA — Indiana University, Kelley School of Business (1996)
Personal Likes & Life
- Distinguished Eagle Scout; serves on Purdue's board of trustees and Adobe's board
- Born in Bloomington, Indiana, raised largely in California, then 'returned' twice — to Purdue, then to Indiana University for his MBA
- Publicly frames leadership as casting a shadow: 'what you model doing — the shadow you cast — matters' (Posse Foundation interview, 2019)
Past Experience
Business development associate working on M&A, straight after his Kelley MBA.
Marketing and sales leadership; president and general manager of Lilly China; president of Lilly USA; senior VP and president of Lilly Bio-Medicines.
Succeeds John Lechleiter at 49, inheriting ~$23bn of revenue and a pipeline-dependent future.
Adds the chairmanship; the tirzepatide era begins — Mounjaro (2022) and Zepbound (2023) redefine the company.
🏆 Achievements
- The GLP-1 transformation: revenue from $22.9bn (2017) to $65.2bn (2025), with 2026 guidance of $80–83bn — and Lilly the first healthcare company to pass a $1 trillion valuation
- Named Chief Executive magazine's CEO of the Year (2025); Lilly's market cap up more than tenfold on his tenure
- Manufacturing as strategy: the largest production build-out in Lilly's 150 years, announced plant by plant across the US
🎙️ Interviews to Watch / Read
NPR — Ricks explains Lilly's insulin price cuts (Mar 2023)https://www.northcountrypublicradio.org/news/npr/1160457074/eli-lilly-ceo-david-ricks-comments-on-why-it-s-cutting-insulin-prices-now ↗Cheeky Pint — Ricks on PBMs, LillyDirect and disintermediation (via Webull News)
https://www.webull.com/news/13843789309928448 ↗
⚠️ Failures & Setbacks
- Insulin pricing legacy — Lilly held list prices that reached ~$274 a vial for years before the 2023 cuts; the Senate Finance Committee's 2021 report documented the system's toll under his early tenure
- Supply failure at peak demand: 2023–24 GLP-1 shortages put Mounjaro and Zepbound on FDA shortage lists while compounders filled the gap
- Concentration risk is the standing critique: a majority of growth rides on one molecule family (tirzepatide), with the orforglipron readouts carrying outsized weight